• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钠-葡萄糖协同转运蛋白 2 抑制剂:心内科医生的实用考虑和建议。

SGLT2 inhibitors: practical considerations and recommendations for cardiologists.

机构信息

Institute of Medical Science, University of Toronto.

Faculty of Medicine, University of Toronto.

出版信息

Curr Opin Cardiol. 2018 Nov;33(6):676-682. doi: 10.1097/HCO.0000000000000561.

DOI:10.1097/HCO.0000000000000561
PMID:30148719
Abstract

PURPOSE OF REVIEW

To address common concerns regarding sodium-glucose cotransporter 2 (SGLT2) inhibitor use for patients with type 2 diabetes mellitus (T2DM) in cardiovascular practice.

RECENT FINDINGS

SGLT2 inhibitors provide glycemic control and improve cardiovascular and renal endpoints in T2DM. Cardiovascular outcome trials have demonstrated sustained cardiovascular, heart failure and renal benefits independent of glycemic control, which persist down to an eGFR of 30 ml/min/1.73 m. SGLT2 inhibitors can be safely administered alongside common diuretics, and routine monitoring of renal function is advised at initiation of therapy, particularly for patients on loop diuretics. Mild initial reductions in eGFR are expected, usually stabilizing over time. The most common adverse effect noted with SGLT2 inhibitors is genital mycotic infections, primarily in women. Less common, but concerning effects associated with canagliflozin include increased risk of fractures and lower limb amputations, particularly in patients with previous amputation history. Overall, SGLT2 inhibitors are well tolerated and effective adjuncts to diabetic treatment, for which the benefits seem to outweigh the risks.

SUMMARY

The care of patients with T2DM requires an interdisciplinary team approach, within which the role of cardiologists is expanding. SGLT2 inhibitors are an encouraging treatment option for achieving glycemic control, whilst also improving cardiovascular and renal outcomes.

摘要

目的综述

解决在心血管疾病实践中,2 型糖尿病(T2DM)患者使用钠-葡萄糖共转运蛋白 2(SGLT2)抑制剂的常见问题。

最新发现

SGLT2 抑制剂可控制血糖,改善 T2DM 的心血管和肾脏结局。心血管结局试验显示,SGLT2 抑制剂具有持续的心血管、心力衰竭和肾脏获益,独立于血糖控制,甚至在 eGFR 低至 30ml/min/1.73m 时仍持续存在。SGLT2 抑制剂可与常用利尿剂安全合用,建议在开始治疗时监测肾功能,特别是对于使用袢利尿剂的患者。预计最初会出现 eGFR 轻度下降,通常会随时间稳定。SGLT2 抑制剂最常见的不良反应是生殖器真菌感染,主要发生在女性。坎格列净相关的不太常见但令人担忧的影响包括骨折和下肢截肢风险增加,特别是对于有既往截肢史的患者。总体而言,SGLT2 抑制剂耐受性良好,是糖尿病治疗的有效辅助手段,其益处似乎超过了风险。

总结

T2DM 患者的治疗需要多学科团队的方法,其中心脏病专家的角色正在扩大。SGLT2 抑制剂是一种有前途的治疗选择,可控制血糖,同时改善心血管和肾脏结局。

相似文献

1
SGLT2 inhibitors: practical considerations and recommendations for cardiologists.钠-葡萄糖协同转运蛋白 2 抑制剂:心内科医生的实用考虑和建议。
Curr Opin Cardiol. 2018 Nov;33(6):676-682. doi: 10.1097/HCO.0000000000000561.
2
Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.钠-葡萄糖共转运蛋白 2(SGLT2)抑制剂的肾脏和心脏影响:科学现状。
Ann Pharmacother. 2018 Dec;52(12):1238-1249. doi: 10.1177/1060028018783661. Epub 2018 Jun 17.
3
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.钠-葡萄糖共转运蛋白 2 抑制剂的肾脏保护作用。
Kidney Int. 2018 Jul;94(1):26-39. doi: 10.1016/j.kint.2017.12.027. Epub 2018 May 5.
4
SGLT2 Inhibitors and the Diabetic Kidney.钠-葡萄糖协同转运蛋白 2 抑制剂与糖尿病肾脏疾病
Diabetes Care. 2016 Aug;39 Suppl 2:S165-71. doi: 10.2337/dcS15-3006.
5
The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.CANVAS 项目:卡格列净对降低 2 型糖尿病患者心血管风险的影响。
Cardiovasc Diabetol. 2019 May 28;18(1):64. doi: 10.1186/s12933-019-0869-2.
6
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.SGLT2 抑制剂对 2 型糖尿病合并慢性肾脏病患者心血管、肾脏和安全性结局的影响:系统评价和荟萃分析。
Diabetes Obes Metab. 2019 May;21(5):1237-1250. doi: 10.1111/dom.13648. Epub 2019 Mar 4.
7
The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.SGLT2 抑制剂治疗 2 型糖尿病的药代动力学和药效学:最新进展。
Expert Opin Drug Metab Toxicol. 2018 Dec;14(12):1287-1302. doi: 10.1080/17425255.2018.1551877. Epub 2018 Nov 29.
8
The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes.房间里的大象:为什么心脏病学家不应再忽视 2 型糖尿病。
Prog Cardiovasc Dis. 2019 Jul-Aug;62(4):364-369. doi: 10.1016/j.pcad.2019.08.001. Epub 2019 Aug 10.
9
The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病早期治疗中的潜在作用。
Int J Clin Pract. 2015 Oct;69(10):1071-87. doi: 10.1111/ijcp.12675. Epub 2015 Jul 5.
10
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.在 2 型糖尿病中使用 SGLT2 抑制剂:权衡风险与获益。
Diabetologia. 2018 Oct;61(10):2118-2125. doi: 10.1007/s00125-018-4663-6. Epub 2018 Aug 22.

引用本文的文献

1
Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review.SGLT2 抑制剂在射血分数降低的心力衰竭患者中的应用的临床考虑:综述。
Adv Ther. 2022 Aug;39(8):3472-3487. doi: 10.1007/s12325-022-02169-3. Epub 2022 Jun 14.
2
Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently.明确钠-葡萄糖协同转运蛋白2抑制剂在基层医疗中的作用:是时候换个角度思考了。
Diabetes Ther. 2022 May;13(5):889-911. doi: 10.1007/s13300-022-01242-y. Epub 2022 Mar 29.
3
Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
钠-葡萄糖共转运蛋白 2 抑制剂在心力衰竭预防和治疗中的临床应用:超越 2 型糖尿病。一篇叙述性综述。
Adv Ther. 2022 Feb;39(2):845-861. doi: 10.1007/s12325-021-01989-z. Epub 2021 Dec 9.
4
SGLT2 Inhibitors, What the Emergency Physician Needs to Know: A Narrative Review.钠-葡萄糖协同转运蛋白2抑制剂,急诊医生需要了解的内容:一篇叙述性综述
J Clin Med. 2021 May 10;10(9):2036. doi: 10.3390/jcm10092036.
5
Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry.糖尿病与心肌梗死后年轻成年人长期预后不良相关:Partners YOUNG-MI 登记研究。
Diabetes Care. 2020 Aug;43(8):1843-1850. doi: 10.2337/dc19-0998. Epub 2019 Sep 23.
6
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice.钠-葡萄糖协同转运蛋白2抑制剂:糖化血红蛋白之外的心血管益处——将证据转化为实践
Diabetes Ther. 2019 Oct;10(5):1595-1622. doi: 10.1007/s13300-019-0657-8. Epub 2019 Jul 9.